{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T02:12:39Z","timestamp":1792375959966,"version":"4.4.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T00:00:00Z","timestamp":1630886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T00:00:00Z","timestamp":1630886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s00415-021-10793-2","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T12:02:56Z","timestamp":1630929776000},"page":"2064-2072","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Adalimumab for CNS sarcoidosis: single-center experience and literature review"],"prefix":"10.1007","volume":"269","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5644-9638","authenticated-orcid":false,"given":"Spencer K.","family":"Hutto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4463-3486","authenticated-orcid":false,"given":"Kevin","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1129-0050","authenticated-orcid":false,"given":"Julien J.","family":"Cavanagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haatem","family":"Reda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagagopal","family":"Venna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,6]]},"reference":[{"key":"10793_CR1","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1056\/NEJMra071714","volume":"35","author":"MC Iannuzzi","year":"2007","unstructured":"Iannuzzi MC, Rybicki BA, Teirstein AS (2007) Sarcoidosis. N Engl J Med 35:2153\u20132165","journal-title":"N Engl J Med"},{"issue":"6","key":"10793_CR2","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2165\/00063030-200317060-00005","volume":"17","author":"RP Baughman","year":"2003","unstructured":"Baughman RP, Iannuzzi M (2003) Tumour necrosis factor in sarcoidosis and its potential for targeted therapy. BioDrugs 17(6):425\u2013431","journal-title":"BioDrugs"},{"key":"10793_CR3","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1212\/WNL.0000000000004644","volume":"89","author":"JM Gelfand","year":"2017","unstructured":"Gelfand JM, Bradshaw MJ, Stern BJ et al (2017) Infliximab for the treatment of CNS sarcoidosis: a multi-institutional series. Neurology 89:2092\u20132100","journal-title":"Neurology"},{"key":"10793_CR4","first-page":"76","volume":"25","author":"RP Baughman","year":"2008","unstructured":"Baughman RP, Lower EE, Drent M (2008) Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them. Sarcoid Vasc Dif Lung Dis 25:76\u201389","journal-title":"Sarcoid Vasc Dif Lung Dis"},{"key":"10793_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.rmed.2016.04.011","volume":"115","author":"HA Crommelin","year":"2016","unstructured":"Crommelin HA, van der Burg LM, Vorselaars ADM et al (2016) Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab. Respir Med 115:72\u201377","journal-title":"Respir Med"},{"key":"10793_CR6","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/j.1752-699X.2011.00276.x","volume":"6","author":"N Milman","year":"2012","unstructured":"Milman N, Graudal N, Loft A et al (2012) Effect of the TNF-\u03b1 inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET. Clin Respir J 6:238\u2013247","journal-title":"Clin Respir J"},{"key":"10793_CR7","doi-asserted-by":"publisher","first-page":"e010952","DOI":"10.1161\/JAHA.118.010952","volume":"8","author":"DG Rosenthal","year":"2019","unstructured":"Rosenthal DG, Parwani P, Murray TO et al (2019) Long-term corticosteroid-sparing immunosuppression for cardiac sarcoidosis. J Am Heart Assoc 8:e010952","journal-title":"J Am Heart Assoc"},{"key":"10793_CR8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00415-009-0077-1","volume":"256","author":"M Marnane","year":"2009","unstructured":"Marnane M, Lynch T, Scott J, Stack J, Kelly PJ (2009) Steroid-unresponsive neurosarcoidosis successfully treated with adalimumab. J Neurol 256:139\u2013140","journal-title":"J Neurol"},{"key":"10793_CR9","first-page":"275","volume":"32","author":"L Riancho-Zarrabeitia","year":"2014","unstructured":"Riancho-Zarrabeitia L, Delgado-Alvarado M, Riancho J et al (2014) Anti-TNF-\u03b1 in the management of severe neurosarcoidosis: a report of five cases from a single centre and literature review. Clin Exp Rheumatol 32:275\u2013284","journal-title":"Clin Exp Rheumatol"},{"key":"10793_CR10","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1001\/jamaneurol.2018.2295","volume":"75","author":"BJ Stern","year":"2018","unstructured":"Stern BJ, Royal W, Gelfand JM et al (2018) Definition and consensus diagnostic criteria for neurosarcoidosis: from the Neurosarcoidosis Consortium Consensus Group. JAMA Neurol 75:1546\u20131553","journal-title":"JAMA Neurol"},{"issue":"2","key":"10793_CR11","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/1756-185X.12122","volume":"17","author":"S Metyas","year":"2014","unstructured":"Metyas S, Tawadrous M, Yeter KC, Arkfeld DG (2014) Neurosarcoidosis mimicking multiple sclerosis successfully treated with methotrexate and adalimumab. Int J Rheum Dis 17(2):214\u2013216","journal-title":"Int J Rheum Dis"},{"key":"10793_CR12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","volume":"31","author":"V Strand","year":"2017","unstructured":"Strand V, Balsa A, Al-Saleh J et al (2017) Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs 31:299\u2013316","journal-title":"BioDrugs"},{"key":"10793_CR13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","volume":"142","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, van Assche G, Reinisch W et al (2012) Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142:257\u2013265","journal-title":"Gastroenterology"},{"key":"10793_CR14","doi-asserted-by":"publisher","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","volume":"157","author":"AB Kimball","year":"2012","unstructured":"Kimball AB, Kerdel F, Adams D et al (2012) Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med 157:846\u2013855","journal-title":"Ann Intern Med"},{"key":"10793_CR15","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","volume":"132","author":"JF Colombel","year":"2007","unstructured":"Colombel JF, Sandborn WJ, Rutgeerts P et al (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: The CHARM Trial. Gastroenterology 132:52\u201365","journal-title":"Gastroenterology"},{"key":"10793_CR16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","volume":"130","author":"SB Hanauer","year":"2006","unstructured":"Hanauer SB, Sandborn WJ, Rutgeerts P et al (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial. Gastroenterology 130:323\u2013333","journal-title":"Gastroenterology"},{"key":"10793_CR17","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1212\/WNL.0000000000003431","volume":"87","author":"S Bitoun","year":"2016","unstructured":"Bitoun S, Bouvry D, Borie R et al (2016) Treatment of neurosarcoidosis: a comparative study of methotrexate and mycophenolate mofetil. Neurology 87:2517\u20132521","journal-title":"Neurology"},{"key":"10793_CR18","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/annrheumdis-2012-202545","volume":"72","author":"FB Vincent","year":"2013","unstructured":"Vincent FB, Morand EF, Murphy K et al (2013) Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralizing agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 72:165\u2013178","journal-title":"Ann Rheum Dis"},{"issue":"14","key":"10793_CR19","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2011.406","volume":"305","author":"GM Bertelds","year":"2011","unstructured":"Bertelds GM, Krieckaert CLM, Nurmohamed MT et al (2011) Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305(14):1460\u20131468","journal-title":"JAMA"},{"key":"10793_CR20","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1136\/ard.2009.109702","volume":"68","author":"MK de Vries","year":"2009","unstructured":"de Vries MK, Brouwer E, van der Horst-Bruinsma IE et al (2009) Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. Ann Rheum Dis 68:1787\u20131788","journal-title":"Ann Rheum Dis"},{"key":"10793_CR21","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1136\/ard.2006.065615","volume":"66","author":"GM Bartelds","year":"2007","unstructured":"Bartelds GM, Wijbrandts CA, Nurmohamed MT et al (2007) Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 66:921\u2013926","journal-title":"Ann Rheum Dis"},{"key":"10793_CR22","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1136\/annrheumdis-2012-202220","volume":"72","author":"S Garc\u00eas","year":"2013","unstructured":"Garc\u00eas S, Demengeot J, Benito-Garcia E (2013) The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 72:1947\u20131955","journal-title":"Ann Rheum Dis"},{"key":"10793_CR23","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1136\/archdischild-2018-315060","volume":"104","author":"A Skrabl-Baumgartner","year":"2019","unstructured":"Skrabl-Baumgartner A, Seidel G, Langner-Wegscheider B, Schlagenhauf A, Jahnel J (2019) Drug monitoring in long-term treatment with adalimumab for juvenile idiopathic arthritis-associated uveitis. Arch Dis Child 104:246\u2013250","journal-title":"Arch Dis Child"},{"key":"10793_CR24","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1136\/gut.2006.099978","volume":"56","author":"S Vermeire","year":"2007","unstructured":"Vermeire S, Noman M, Assche GV et al (2007) Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn\u2019s disease. Gut 56:1226\u20131231","journal-title":"Gut"},{"issue":"9","key":"10793_CR25","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","volume":"41","author":"RN Maini","year":"1998","unstructured":"Maini RN, Breedveld FC, Kalden JR et al (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor \u03b1 monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41(9):1552\u20131563","journal-title":"Arthritis Rheum"},{"key":"10793_CR26","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1212\/WNL.0000000000002992","volume":"87","author":"NL Zalewski","year":"2016","unstructured":"Zalewski NL, Krecke KN, Weinshenker BG et al (2016) Central canal enhancement and the trident sign in spinal cord sarcoidosis. Neurology 87:743\u2013744","journal-title":"Neurology"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10793-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-021-10793-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10793-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T16:09:52Z","timestamp":1647965392000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-021-10793-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,6]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10793"],"URL":"https:\/\/doi.org\/10.1007\/s00415-021-10793-2","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,6]]},"assertion":[{"value":"3 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors report no disclosures relevant to the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The Mass General Brigham Institutional Review Board approved this study. Subject to ethics board approvals, data will be made available upon request to qualified investigators. The authors have no conflicts of interest to declare that are relevant to the content of this article. The authors did not receive support from any organization for the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}